Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case of tularemia after an endurance run in a non-endemic region.

Literature DB >> 23074014

A case of tularemia after an endurance run in a non-endemic region.

R Meckenstock¹, A Therby, A Le Monnier, D Khau, S Monnier, B Pangon, A Greder-Belan.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2012 PMID： 23074014 DOI： 10.1007/s15010-012-0350-6

Source DB: PubMed Journal: Infection ISSN： 0300-8126 Impact factor: 3.553

Keyword Cloud
References

× No keyword cloud information.

19 in total

1. Ciprofloxacin for treatment of tularemia.

Authors: A Johansson; L Berglund; A Sjöstedt; A Tärnvik
Journal: Clin Infect Dis Date: 2001-07-15 Impact factor: 9.079

2. Human tularemia in France, 2006-2010.

Authors: Max Maurin; Isabelle Pelloux; Jean Paul Brion; Jeanne-Noëlle Del Banõ; Aleth Picard
Journal: Clin Infect Dis Date: 2011-11 Impact factor: 9.079

3. Francisella tularensis bacteremia.

Authors: X Haristoy; A Lozniewski; C Tram; D Simeon; L Bevanger; C Lion
Journal: J Clin Microbiol Date: 2003-06 Impact factor: 5.948

4. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence.

Authors: Jeffrey R Barker; Audrey Chong; Tara D Wehrly; Jieh-Juen Yu; Stephen A Rodriguez; Jirong Liu; Jean Celli; Bernard P Arulanandam; Karl E Klose
Journal: Mol Microbiol Date: 2009-12 Impact factor: 3.501

A case of tularemia after an endurance run in a non-endemic region.

1. Ciprofloxacin for treatment of tularemia.

2. Human tularemia in France, 2006-2010.

3. Francisella tularensis bacteremia.

4. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence.

Review 5. Streptomycin and alternative agents for the treatment of tularemia: review of the literature.

Review 6. Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options.

7. Molecular Epidemiology of Francisella tularensis in the United States.

8. The subversion of the immune system by francisella tularensis.

9. The francisella intracellular life cycle: toward molecular mechanisms of intracellular survival and proliferation.

10. Real-time PCR for diagnosis of oculoglandular tularemia.